158 related articles for article (PubMed ID: 17126057)
1. Contribution of pharmacoepidemiological studies to the evaluation of treatment-related adverse events.
Suissa S
Joint Bone Spine; 2006 Dec; 73(6):627-8. PubMed ID: 17126057
[No Abstract] [Full Text] [Related]
2. Pharmacoepidemiology and rheumatic diseases: 2001-2002.
Solomon DH; Avorn J
Curr Opin Rheumatol; 2003 Mar; 15(2):122-6. PubMed ID: 12598798
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoepidemiology and rheumatic disorders.
Chan KA; Hernandez-Diaz S
Rheum Dis Clin North Am; 2004 Nov; 30(4):835-50, vii. PubMed ID: 15488696
[TBL] [Abstract][Full Text] [Related]
4. Tuberculosis associated with therapy against tumor necrosis factor alpha.
Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
[No Abstract] [Full Text] [Related]
5. Pediatric rheumatic disease: Vaccination in pediatric rheumatic disease--risks and benefits.
Janow G; Ilowite NT
Nat Rev Rheumatol; 2012 Feb; 8(4):188-90. PubMed ID: 22331060
[No Abstract] [Full Text] [Related]
6. Safe and well tolerated.
Fleischmann R; Goodson N; Elewaut D
Rheumatology (Oxford); 2011 Nov; 50(11):1942-3. PubMed ID: 21994400
[No Abstract] [Full Text] [Related]
7. Family Planning Counseling for Women With Rheumatic Diseases.
Birru Talabi M; Clowse MEB; Schwarz EB; Callegari LS; Moreland L; Borrero S
Arthritis Care Res (Hoboken); 2018 Feb; 70(2):169-174. PubMed ID: 28437837
[No Abstract] [Full Text] [Related]
8. Recent advances in Pediatric Rheumatology: July 2015-June 2016.
Sharma A; Vignesh P; Jindal AK; Gupta A
Int J Rheum Dis; 2017 Apr; 20(4):504-509. PubMed ID: 28205425
[No Abstract] [Full Text] [Related]
9. Adverse drug reactions and their measurement in the rheumatic diseases.
Day RO; Quinn DI; Conaghan PG; Tett SE
J Rheumatol; 1995 May; 22(5):983-8. PubMed ID: 8587095
[TBL] [Abstract][Full Text] [Related]
10. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.
Carmona L; Descalzo MA; Ruiz-Montesinos D; Manero-Ruiz FJ; Perez-Pampin E; Gomez-Reino JJ;
Rheumatology (Oxford); 2011 Jan; 50(1):85-92. PubMed ID: 20601654
[TBL] [Abstract][Full Text] [Related]
11. How to ascertain drug safety in the context of benefit. Controversies and concerns.
Simon LS; Strand CV; Boers M; Brooks PM; Tugwell PS; Bombardier C; Fries JF; Henry D; Goldkind L; Guyatt G; Laupacis A; Lynd L; Macdonald T; Mamdani M; Moore A; Saag KG; Silman AJ; Stevens R; Tyndall A
J Rheumatol; 2009 Sep; 36(9):2114-21. PubMed ID: 19738223
[TBL] [Abstract][Full Text] [Related]
12. Disease modifying antirheumatic drugs and pregnancy.
Uhl K; Kennedy DL; Gilliland WR
J Rheumatol; 2004 Feb; 31(2):400-1; author reply 401-2. PubMed ID: 14760818
[No Abstract] [Full Text] [Related]
13. Reproductive Health.
Weisman MH
Rheum Dis Clin North Am; 2017 May; 43(2):xi-xii. PubMed ID: 28390571
[No Abstract] [Full Text] [Related]
14. Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study.
Lohse A; Bossert M; Bozgan AM; Charpentier A; Guillochon C; Bourgoin C; Balblanc JC; Conrozier T
Clin Exp Rheumatol; 2020; 38(6):1273. PubMed ID: 33253100
[No Abstract] [Full Text] [Related]
15. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
Khasnis AA; Calabrese LH
Semin Arthritis Rheum; 2010 Oct; 40(2):147-63. PubMed ID: 19914686
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics in the rheumatic diseases.
Cronstein BN
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii25-ii27. PubMed ID: 15479867
[No Abstract] [Full Text] [Related]
17. Disease-modifying antirheumatic drugs.
Belavic J
Nursing; 2010 Nov; 40(11):20. PubMed ID: 20975424
[No Abstract] [Full Text] [Related]
18. Long-term use of antimalarial drugs in rheumatic diseases.
Jover JA; Leon L; Pato E; Loza E; Rosales Z; Matias MA; Mendez-Fernandez R; Díaz-Valle D; Benitez-Del-Castillo JM; Abasolo L
Clin Exp Rheumatol; 2012; 30(3):380-7. PubMed ID: 22339928
[TBL] [Abstract][Full Text] [Related]
19. [Can we treat with modern antirheumatics? Costs of NSAID treatment].
Bolten WW
Pharm Unserer Zeit; 2002; 31(2):206-15. PubMed ID: 11977457
[No Abstract] [Full Text] [Related]
20. Factors associated with chloroquine-induced retinopathy in rheumatic diseases: comments on the article by Araiza-Casillas et al.
Easterbrook M
Lupus; 2004; 13(8):621. PubMed ID: 15462495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
